Genetic profiling -- implications for refined diagnosis: and treatment of soft tissue sarcomas.
Soft tissue sarcomas (STS) are challenging as they represent a morphologically and genetically heterogeneous groups of tumors. A multitude of genetic changes, often in the form of fusion genes, were recognized during the 1980's and now constitute a diagnostic lexicon in several STS subtypes, whereas...
| Publicado en: | Acta Orthopaedica (Supplement) Vol. 80; pp. 15 - 24 |
|---|---|
| Autores principales: | , |
| Formato: | tables/charts Journal Article |
| Publicado: |
Medical Journals Sweden AB
Apr2009 Supplement 334
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105398856&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 105398856 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 17453690 1WHY jtl: Acta Orthopaedica (Supplement) issn: 17453690 maglogo: N pubinfo: dt: Apr2009 Supplement 334 vid: 80 pid: 59195 pub: Medical Journals Sweden AB artinfo: ui: 105398856 105398856 2010362830 105398856 ppf: 15 ppct: 9 formats: fmt: @attributes: type: P tig: atl: Genetic profiling -- implications for refined diagnosis: and treatment of soft tissue sarcomas. aug: au: Carneiro A Nilbert M affil: Department of Oncology, Institute of Clinical Sciences, Lund University and Lund University Hospital, Lund, Sweden; Ana.Carneiro@med.lu.se sug: subj: Genetic Techniques Sarcoma Diagnosis Sarcoma Familial and Genetic Angiogenesis Inhibitors Anoxia Physiopathology Decision Making, Clinical Drug Design Genetics Karyotyping Neovascularization, Physiologic Sarcoma Prognosis Sarcoma Therapy ab: Soft tissue sarcomas (STS) are challenging as they represent a morphologically and genetically heterogeneous groups of tumors. A multitude of genetic changes, often in the form of fusion genes, were recognized during the 1980's and now constitute a diagnostic lexicon in several STS subtypes, whereas many of the more common subtypes are genetically complex without distinct alterations. Refined STS management requires improved diagnostic reproducibility, novel prognosticators, and introduction of targeted therapies. In recent years, a number of genetic profiling studies DS analyzing copy-number alterations as well as gene expression changes DS have deepened our understanding of STS development through demonstration of recurrently deregulated tumorigenic pathways. The challenge is now to bring the genetic profiles into clinical decision-making. This review, in conjunction with the Scandinavian Sarcoma Group's (SSG) 30 years jubilee, discusses how the information from genetic profiling studies may be translated into clinical practice for refined diagnostics, prognostics, and treatment of STS. pubtype: Academic Journal doctype: tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|